Vitamin K1 and Reduced Acneiform Rash Incidence

Time to effect

Median: 4 weeks · IQR 4 weeks–4 weeks · Range 4 weeks–4 weeks — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityNo significant differenceHR=1.33; 95% CI, 0.57-3.10; p=0.507
Prophylactic application of topical vitamin K1 cream did not decrease the risk of acneiform rash (HR=1.33; 95% CI, 0.57-3.10; p=0.507).
from: Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab trea

1 of 1 paper

Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.

2013-01
Clinical Trial · n = 61
European journal of dermatology : EJD 23(1)
- Jae-Cheol Jo
- Yong Sang Hong
- Kyu-pyo Kim
- Jae-Lyun Lee
- Hwa Jung Kim
- Mi-Woo Lee
- Seok-Byung Lim
- Chang Sik Yu
- Jin Cheon Kim
- Jong Hoon Kim
- Tae Won Kim

PubMed: 23238388
DOI: 10.1684/ejd.2012.1899

3 Insights on

Reduced Acneiform Rash Incidence

High evidence
Clinical

The incidence of grade≥2 acneiform rash after 4 weeks of cetuximab treatment was 42.5% in the historical control group and 55.5% in the experimental group. Prophylactic application of topical vitamin K1 cream did not decrease the risk of acneiform rash (HR=1.33; 95% CI, 0.57-3.10; p=0.507).

Effect: Neutral
Effect size: Small
Significant: No